Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) EPS (Weighted Average and Diluted) (2021 - 2026)

PharmaCyte Biotech (PMCB) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$1.24 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 217.95% to -$1.24 in Q4 2025 year-over-year; TTM through Oct 2025 was -$0.79, a 187.78% decrease, with the full-year FY2025 number at $3.19, up 277.22% from a year prior.
  • EPS (Weighted Average and Diluted) was -$1.24 for Q4 2025 at PharmaCyte Biotech, down from -$1.23 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.12 in Q2 2025 to a low of -$1.24 in Q4 2025.
  • A 5-year average of -$0.11 and a median of -$0.21 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Biggest YoY gain for EPS (Weighted Average and Diluted) was 778.57% in 2024; the steepest drop was 3200.0% in 2024.
  • PharmaCyte Biotech's EPS (Weighted Average and Diluted) stood at $0.43 in 2021, then crashed by 123.26% to -$0.1 in 2022, then tumbled by 111.36% to -$0.21 in 2023, then crashed by 84.52% to -$0.39 in 2024, then crashed by 217.95% to -$1.24 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's EPS (Weighted Average and Diluted) are -$1.24 (Q4 2025), -$1.23 (Q3 2025), and $2.12 (Q2 2025).